SCHEMBL5222332

SCHEMBL5222332

CC(C)(C)OC(=O)N1CCC(Cc2cc(F)c(O)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.43
HTT P42858 3/20 0.43
DPP4 P27487 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
NPBWR1 P48145 1/20 0.42
KMT2A Q03164 1/20 0.42
MCHR1 Q99705 1/20 0.42
SCN9A Q15858 1/20 0.41
NR1D1 P20393 1/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
GPR174 Q9BXC1 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216291 0.83 SMN1; SMN2 (0.45) GPR119HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL5217501 0.83 SCN9A (0.42) GPR119HTTDPP4SMN1; SMN2LMNA
SCHEMBL18280182 0.82 DPP4 (0.51) GPR119DPP4SCN9AMAPTKDM4E
SCHEMBL24582171 0.82 MAPT (0.46) GPR119DPP4SMN1; SMN2LMNAALDH1A1
SCHEMBL5214538 0.82 DPP4 (0.48) GPR119DPP4SMN1; SMN2LMNAALDH1A1
SCHEMBL16113557 0.79 GPR119 (0.49) GPR119DPP4LMNASCN9AMAPT
SCHEMBL18280030 0.78 DPP4 (0.52) GPR119DPP4ALDH1A1SCN9AKDM4E
SCHEMBL22265458 0.78 GPR119 (0.47) GPR119DPP4SCN9AMAPTKDM4E
SCHEMBL30679858 0.78 GPR119 (0.49) GPR119DPP4SCN9AMAPTKDM4E
SCHEMBL4773795 0.77 LMNA (0.61) GPR119HTTSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330460-B1 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2007-03-21 EP disclosed
US-6939871-B2 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C. (GB) 2005-09-06 US disclosed
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C (GB) 2004-04-01 US disclosed
EP-1330460-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2003-07-30 EP disclosed
WO-2002034754-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use CYP2B6, CBR1, CYP2A6 GPR119 1394/4885HTT 2603/4885DPP4 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.